autologous anti-cd 123 car tcr/4-1bb-expressing t-lymphocytes
Cell therapyexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2015 (NCT02623582)
Timeline
2010s
- Jan 1, 2015
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Interleukin-3 receptor subunit alphaImmunity, passive
IL3RA immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- autologous anti-cd 123 car tcr/4-1bb-expressing t-lymphocytes
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02623582 | Early Phase 1 (Phase 1) | Dec 1, 2015 | University of Pennsylvania |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of Pennsylvania | Academic/Hospital | 1 | 1 | 1 | 2015 |
1 organizations
Page 1 / 1